318 related articles for article (PubMed ID: 30624546)
1. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
[TBL] [Abstract][Full Text] [Related]
2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
[TBL] [Abstract][Full Text] [Related]
5. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
7. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
8. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
9. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
10. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
12. Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW; Hawkins DS
Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
[No Abstract] [Full Text] [Related]
13. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
14. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
16. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
18. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U
Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib: First Global Approval.
Scott LJ
Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
